This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Choy, H. Articles by Yao, M. PubMed PubMed Citation Articles by Choy, H. Articles by Yao, M. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Small Molecules Clinical Research: Clinical Trials

Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue

Authors' Affiliation: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas

Requests for reprints: Hak Choy, Moncrief Radiation Oncology Center, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX 75390-9183. Phone: 214-645-7620; Fax: 214-645-7622; E-mail: Hak.Choy{at}UTsouthwestern.edu.

Abstract

Platinum drugs are major chemotherapeutic agents that are used alone or in combination with other systemic agents and/or radiation therapy in the management of many human malignancies. All three platinum drugs approved by the Food and Drug Administration, cisplatin, carboplatin, and oxaliplatin, are administrated intravenously. Satraplatin is the first orally administered platinum drug under active clinical investigation. Satraplatin and its major metabolite, JM118, have shown antineoplastic activity in in vitro, in vivo, and in clinical settings. Use of satraplatin as an alternative platinum cytotoxic agent is particularly attractive because of the convenience of administration, milder toxicity profile, lack of cross-resistance with cisplatin, theoretical advantage as a radiosensitizer, and activity in cancers historically nonresponsive to platinum drugs. The most mature clinical data for satraplatin come from the recently completed phase III trial that investigated the efficacy of satraplatin and prednisone on hormone-refractory prostate cancer patients who had failed a course of other chemotherapy agents. Preliminary reports show that the combination is statistically superior to placebo and prednisone in multiple end points, including progression-free survival, prostate-specific antigen response, objective tumor response, pain response, and duration of pain response. The difference in overall survival, however, did not reach statistical significance.

This article has been cited by other articles:

				G. C. Prendergast Refining Cytotoxic Therapy: Progress in Generalized Therapeutics for Cancer Cancer Reviews Online Content, April 1, 2008; 2008(4): 7 - 7. [Full Text] [PDF]